# Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer

> **NCT04429633** · NA · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 136 (estimated)

## Conditions studied

- Cardiotoxicity
- Breast Cancer
- Prevention
- Adjuvant
- Trastuzumab

## Interventions

- **DRUG:** Candesartan

## Key facts

- **NCT ID:** NCT04429633
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-19
- **Primary completion:** 2022-07-18
- **Final completion:** 2023-07-18
- **Target enrollment:** 136 (ESTIMATED)
- **Last updated:** 2020-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04429633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04429633, "Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04429633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*